<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00668317</url>
  </required_header>
  <id_info>
    <org_study_id>2006-004102-13</org_study_id>
    <nct_id>NCT00668317</nct_id>
  </id_info>
  <brief_title>Bronchial Hyper-responsiveness in Reflux Cough</brief_title>
  <official_title>An 8 Week Non-selected Cohort Study to Investigate Whether the Treatment of Reflux Induced Cough Alters Associated Bronchial Hyper-responsiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hull and East Yorkshire Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hull and East Yorkshire Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim is to determine the effect of 8 weeks of anti-reflux treatment (full acid
      suppression) on bronchial hyper-responsiveness and whether there is a symptomatic
      improvement.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Primary care physicians began prescribing antacid therapy for chronic cough
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Methacholine Sensitivity</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Concentration of methacholine (mg/ml) at which participants forced expired volume in 1 sec (FEV1) is reduced by 20% (the provocation concentration of methacholine causing a 20% fall in FEV1-PC20).
To measure if there is a significant difference in PC20 recorded at baseline to that recorded following 8 weeks treatment with omeprazole and ranitidine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Cough Symptoms Measured Using Leicester Cough Questionnaire</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Cough</condition>
  <arm_group>
    <arm_group_label>omeprazole and ranitidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg oralomeprazole oral tablet twice daily and ranitidine 300 mg oral tablet once daily nocte</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>20 mg BD tablet 8 weeks duration</description>
    <arm_group_label>omeprazole and ranitidine</arm_group_label>
    <other_name>Losec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine</intervention_name>
    <description>300 mg od nocte tablet 8weeks duration</description>
    <arm_group_label>omeprazole and ranitidine</arm_group_label>
    <other_name>Zantac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive methacholine challenge test PC20 less than 4mg/ml (Can be previously
             documented in patients notes within last 4weeks)

          -  Written informed consent

          -  Patients with a history of chronic cough (at least 3 months duration), and associated
             symptoms of gastro-oesophageal reflux

          -  Male and female subjects of at least 18 yrs of age

          -  Subjects able to perform satisfactory FEV1 manoeuvres

          -  Subjects able to understand the study and co-operate with the study procedures

          -  Subjects who consent to their general practitioner (GP) being informed of their study
             participation

        Exclusion Criteria:

          -  has had a heart attack in the last three months

          -  suffers from angina, hypertension or ischaemic heart disease

          -  has epilepsy for which he/she is taking medication

          -  FEV1&lt; 60% predicted

          -  FEV1&lt;1.6L

          -  Female subjects who are pregnant, or lactating, or who are of child bearing potential
             but are not using contraceptive measures

          -  Suffering from any concomitant disease which may interfere with study procedures or
             evaluation.

          -  A lower respiratory tract infection 4 weeks prior to entry on to study

          -  Participation in another study (use of investigational product) within 30 days
             preceding entry on to study.

          -  Alcohol or drug abuse

          -  Use of opiates to treat cough 1 week prior to enrollment

          -  Subjects who are taking Angiotensin Converting Enzymes (ACE) inhibitors.

          -  Subjects who have significant pathology on most recent chest X-Ray.

          -  Inability to understand the procedures and the implications of a challenge test

          -  Patients already taking or have taken in last 4 weeks PPI and H2 receptor antagonist
             (full acid suppression treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alyn H Morice, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hull and East Yorkshire Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trials Unit , Cardiovascular and respiratory studies, Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <state>East Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <results_first_submitted>March 16, 2012</results_first_submitted>
  <results_first_submitted_qc>October 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2012</results_first_posted>
  <last_update_submitted>October 16, 2012</last_update_submitted>
  <last_update_submitted_qc>October 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hull and East Yorkshire Hospitals NHS Trust</investigator_affiliation>
    <investigator_full_name>Prof A H Morice</investigator_full_name>
    <investigator_title>Professor of Respiratory Medicine</investigator_title>
  </responsible_party>
  <keyword>Hyper-responsiveness, reflux cough</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
    <mesh_term>Bronchial Hyperreactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited at the cough clinic at castleHill Hospital</recruitment_details>
      <pre_assignment_details>Patients had to have a positive methacholine challenge, and reflux associated chronic cough</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Antacid Therapy</title>
          <description>Therapy with omeprazole 20 mg BD and Ranitidine 300mg od nocte</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antacid Therapy</title>
          <description>Therapy with omeprazole 20 mg BD and Ranitidine 300mg od nocte</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.8" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Methacholine Sensitivity</title>
        <description>Concentration of methacholine (mg/ml) at which participants forced expired volume in 1 sec (FEV1) is reduced by 20% (the provocation concentration of methacholine causing a 20% fall in FEV1-PC20).
To measure if there is a significant difference in PC20 recorded at baseline to that recorded following 8 weeks treatment with omeprazole and ranitidine</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <population>All subjects recruited with efficacy data recorded after week T0 will be included in the ITT population for analysis. Assuming a within subject standard deviation(for change in PC20) of no more than 2.71 units, 30 subjects are sufficient to provide 80% power to detect a treatment difference of 1.8 units using a 5% two sided significance test</population>
        <group_list>
          <group group_id="O1">
            <title>Omeprazole and Ranitidine</title>
            <description>Therapy with omeprazole 20 mg twice a day (BD) and Ranitidine 300mg once a day (od) at night (nocte)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Methacholine Sensitivity</title>
          <description>Concentration of methacholine (mg/ml) at which participants forced expired volume in 1 sec (FEV1) is reduced by 20% (the provocation concentration of methacholine causing a 20% fall in FEV1-PC20).
To measure if there is a significant difference in PC20 recorded at baseline to that recorded following 8 weeks treatment with omeprazole and ranitidine</description>
          <population>All subjects recruited with efficacy data recorded after week T0 will be included in the ITT population for analysis. Assuming a within subject standard deviation(for change in PC20) of no more than 2.71 units, 30 subjects are sufficient to provide 80% power to detect a treatment difference of 1.8 units using a 5% two sided significance test</population>
          <units>mg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.598" spread="0.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Cough Symptoms Measured Using Leicester Cough Questionnaire</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 week</time_frame>
      <desc>data collected at each visit of the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Antacid Therapy</title>
          <description>Therapy with omeprazole 20 mg BD and Ranitidine 300mg od nocte</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical trials Manager</name_or_title>
      <organization>Hull and East Yorkshire Hospitals Trust</organization>
      <phone>01482 624067</phone>
      <email>c.e.wright@hull.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

